Study of BRL-201 for hard-to-treat aggressive B-cell lymphoma
Part of Blood & lymphatic, Cancer clinical trials.
This Phase 1 study tests BRL-201 (an anti-CD19 treatment) for safety and early signs of effectiveness in adults with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. It may help people whose lymphoma has returned or not responded to prior treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older and willing to sign informed consent
- Have a lymphoma that is aggressive B-cell non-Hodgkin lymphoma, and test positive for CD19
- Have lymphoma that has come back or is not responding to prior therapy
- Have at least one measurable lymphoma spot on CT/PET scan (or a treated spot that clearly got worse after radiation)
- Have enough body strength to participate (ECOG 0–1) and be healthy enough for the study procedure (blood/organ tests and heart function)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a universal CAR-T cell therapy for patients with non-Hodgkin lymphoma whose cancer cells have CD19 on their surface. It might help if standard treatments have not worked.
This trial tests a new type of CAR-T cell therapy designed to be stronger against B-cell lymphoma that has come back or not responded to previous treatments. The treatment uses your own immune cells, which are modified in a lab to better attack cancer cells.
This trial tests a new type of cell therapy that targets two markers (CD19 and CD20) on lymphoma cells. It is for patients whose lymphoma has come back or has not responded to standard treatments.
This Phase 1 study tests a new type of immune cell therapy (CD19 CAR-T) combined with an anti–PD-1 drug for people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It aims to improve cancer control when standard treatments have not worked or the cancer has come back.
This phase 1 trial tests an investigational treatment called RN1701 for people with certain types of B-cell lymphoma that have come back or not responded to previous therapies. The goal is to see if the drug is safe and effective.
This trial tests a new kind of cell therapy that combines CAR-T cells (which find and kill cancer cells) with an anti-PD1 'armor' to boost their power. It is for adults with diffuse large B-cell lymphoma (DLBCL) that has come back or not responded to earlier treatments.
Hear when a new Non-hodgkin Lymphoma,B Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.